Industry stakeholders see cloud-based collaboration as next step in FDA’s digital health overhaul

Oracle’s cloud bravado masks its database despair
Digital health stakeholders say a cloud-based platform would provide a collaborative approach to the FDA's new regulatory paradigm. (iStockphoto)

Pleased with the Food and Drug Administration’s (FDA) focus on reimagining digital health oversight, industry stakeholders have some thoughts about how the agency should move those efforts forward.

One of those ideas includes the creation of an “integrated online collaboration capability,” a cloud-based platform where manufacturers could submit applications and allow other participating companies to access information on approvals and adverse events.

That approach was fleshed out in a report released by Deloitte this week based on a two-day session with industry stakeholders, startups, patient advocacy groups and FDA regulators. A potential framework emerged from that discussion that emphasized the need for regulators to provide a clear regulatory pathway that uses a risk-based approach and the ability to analyze real-world data from multiple sources.

Featured Webinar

Reducing barriers to patient care: A cross-industry collaboration

Optum will bring together cross-industry experts to share a case study detailing how an employer, provider, payer and pharmaceutical company worked together to address migraines, a hard-to-diagnose condition. Learn how this team started with a model to risk stratify, predict undiagnosed, misdiagnosed and mismanaged members and how those analytics were used to enrich engagement for treatment and diagnosis optimization.

The ideal solution, the report concluded, would be the creation of a secure cloud-based platform that would house the FDA’s regulatory development kit, the new software precertification program and data from a variety of stakeholders, all of which would be accessible by the entire ecosystem. While individual companies would have access to their own proprietary information and application process, broader data sharing on approvals, user adoption and product quality would help organizations navigate the new paradigm.

RELATED: FDA finalizes new guidance to support medical device innovation and ease burden of software updates

“As SaMD [Software as a Medical Device] technology becomes cheaper, more accessible and more sophisticated, it is likely to play an increasingly important role in healthcare delivery, personalized medicin, and medical research,” the analysts wrote. “To realize its full benefit, however, regulation of these devices will need to radically change to accommodate new SaMD manufacturers and the technology’s rapid evolution, and to harness SaMD’s ability to capture RWD to create a collaborative, innovative SaMD community.”

RELATED: FDA’s Scott Gottlieb wants to use funding boost to create a Center of Excellence on Digital Health

Whether the FDA will adopt those suggestions remains to be seen. Last month, FDA Commissioner Scott Gottlieb said if the agency receives an additional $473 million outlined under President Donald Trump’s budget proposal, he plans to create a new Center of Excellence on Digital Health that would oversee the agency’s new regulatory paradigm and include a new cybersecurity unit.

Under Gottlieb, the FDA has made significant changes to the way it plans to regulate digital health tools, launching a new precertification pilot program that includes some of the country’s largest tech companies. Gottlieb has said the agency will remain focused on digital health throughout the year.  

Suggested Articles

A New Jersey medical office has filed suit against Cigna, alleging that the insurer failed to pay for diagnostic testing and treatment for COVID-19.

CMS issued new guidance Friday to help states implement the new interoperability policies in Medicaid and CHIP programs.

GoodRx has released its latest list of the most expensive drugs in America, with orphan drugs and therapies for rare conditions topping the ranking.